The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...
Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and ...
A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...
Number 3: The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and ...